DOI: 10.1055/s-00023610

Drug Research


Kapur A, O’Connor-Semmes R, Hussey EK et al.
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC.

BMC Pharmacol Toxicol 2013;
14: 26

Download Bibliographical Data

Search in: